PS-048 A bar code assisted chemotherapy administration system in cancer patients
| Autor: | M Domínguez López, F García Martín, I Romero Hernández, ME Rodriguez Mateos, FJ Suarez Carrascosa, G Blanco Sánchez, MJ Huertas Fernandez, MV Manzano Martin, MJ Martinez Bautista, A Salguero Olid |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Care process Chemotherapy business.industry medicine.medical_treatment Cancer medicine.disease Surgery Sample size determination Emergency medicine Medicine Medical history Before and after study General Pharmacology Toxicology and Pharmaceutics Error reduction Medical prescription business |
| Zdroj: | European Journal of Hospital Pharmacy. 23:A234.3-A235 |
| ISSN: | 2047-9964 2047-9956 |
| DOI: | 10.1136/ejhpharm-2016-000875.532 |
| Popis: | Background Implementation of new technologies in the drug administration phase (AP) is one of the recommendations suggested by most of the health agencies in order to prevent medication errors (ME). Purpose To asses the effectiveness of a bar code assisted chemotherapy system (BCCS) in cancer patients. Material and methods Prospective before and after study performed in a hospital centre in two phases. Over a 12 month period, ME in the administration were registered by review of the medication orders and medical history. The BCCS (ONCOSCAN) was designed and implemented. A follow-up period of another 12 months was assessed. The difference in rates of ME recorded before and after the BCCS system was implemented was analysed. The main purpose of this technology is to ensure that chemotherapy medication is administered correctly by scanning the bar codes and the preparation label of the medication orders, at the correct dose, at the correct time, at the correct infusion rate, to the correct patient. Sample size was determined to identify an expected error reduction of ME with result of harm to patient of 75% and a type I error of 0.05 with 80% power. Student t tests were used to compare error rates between periods. Results 500 patients were collected, 250 in each period. 6584 prescription lines were reviewed, 3240 in the first period and 3344 in the second period. There were no ME reported at AP in the medical history of the patient in the first period. After implementation of BCCS, 28 ME were detected and avoided (0.84% of intravenous mixtures; p Conclusion Bar code assisted chemotherapy systems allow identification of ME before they reach oncology patients, avoiding harm and increasing the safety of the care process. No conflict of interest. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|